Halozyme Therapeutics Inc. has withdrawn its non-binding proposal to acquire Evotec SE.    Helen Torley, president and CEO of Halozyme, stated, “We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. However, to date, Evotec has been unwilling to engage with us to explore a potential combination and a company spokesperson has publicly commented that its goal...